First Horizon Advisors’s Legend Biotech LEGN Stock Holding History

First Horizon Advisors’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$12.5K	Buy	352 +6	+2%	+$194	﹤0.01%	1601
2025 Q1	$11.7K	Buy	346 +52	+18%	+$1.86K	﹤0.01%	1535
2024 Q4	$9.57K	Buy	294 +45	+18%	+$1.86K	﹤0.01%	1626
2024 Q3	$12.1K	Hold	249	–	–	﹤0.01%	1548
2024 Q2	$11K	Hold	249	–	–	﹤0.01%	1487
2024 Q1	$14K	Hold	249	–	–	﹤0.01%	1471
2023 Q4	$15K	Buy	249 +7	+3%	+$444	﹤0.01%	1441
2023 Q3	$16.3K	Buy	242 +4	+2%	+$278	﹤0.01%	1320
2023 Q2	$16.4K	Buy	238 +5	+2%	+$327	﹤0.01%	1342
2023 Q1	$11.2K	Buy	233 +27	+13%	+$1.32K	﹤0.01%	1513
2022 Q4	$10.3K	Buy	206 +8	+4%	+$388	﹤0.01%	1545
2022 Q3	$8K	Buy	+198	New	+$9.29K	﹤0.01%	1596

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

First Horizon Advisors's LEGN Position: Q2 2025 in Review

First Horizon Advisors increased its Legend Biotech (LEGN) stake by 1.7% in Q2 2025, buying an estimated $194 and bringing the position to 352 shares worth $12.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1601.

First Horizon Advisors first reported a position in LEGN in Q3 2022 and has held it in 12 quarters since. The position peaked at $16.4K in Q2 2023. 211 funds tracked by Wall St. Rank hold LEGN as of Q2 2025.

First Horizon Advisors held 352 shares of Legend Biotech worth $12.5K as of Q2 2025.
First Horizon Advisors bought 6 Legend Biotech shares in Q2 2025, an estimated $194.
Legend Biotech made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1601 holding.
First Horizon Advisors first reported a position in Legend Biotech in Q3 2022 and has held it in 12 quarters since.
First Horizon Advisors's Legend Biotech position peaked at $16.4K in Q2 2023.
211 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.